It is often an on-again, off-again disease, distressing partly because it is so unpredictable. It may defy the conventional wisdom about adherence and early treatment. And escalating prices have undercut cost-effectiveness arguments for the drugs that can keep it in check. Multiple sclerosis is a managed care nightmare.
People with less money have a greater chance of getting dementia. Researchers looked at 6,220 English patients ages 65 and older, in 2002–2003 and again in 2014–2015. In those 12 years, those in the lowest wealth quintile had 1.68 times more likelihood of getting dementia than those in the highest quintile.
The check marks in this table show current health-reform bills cosponsored by 15 key senators.
“Medicare for All won’t work unless we get rid of fee-for-service medicine—period, end of sentence,” says Dean. “Otherwise you’re wasting your time.”
Pharma and Trump administration officials decry them as backroom deals. But payers and PBMs say rebates are an important negotiating tool with drugmakers. Take it away and drug expenditure will go up even faster.
Gene Farber, COO, Reliance ACO: “Reliance ACO is a Track 1 that started in 2014. We have saved CMS over $32 million and have received money back in two of the four years…. I want to scream when anyone, including Seema Verma, says we are not at risk.” There’s more.
They can work, but pharma will need to master the intricacies of adherence metrics, real-world outcomes, and sampling.
But health plans and hospitals are resisting efforts to do more to limit complications during pregnancy and childbirth.
Here’s a list, by no means exhaustive, of think tanks that have developed conservative and libertarian policies and principles in health care
ProPublica has identified key personnel in the Trump health policy apparatus.